Zealand Pharma Industry Trends and Market Analysis

Author

Reads 12K

Free stock photo of pharma
Credit: pexels.com, Free stock photo of pharma

Zealand Pharma has been making waves in the pharmaceutical industry with its innovative approach to treating diabetes and other metabolic disorders.

The company's focus on developing GLP-1 receptor agonists has led to several key partnerships, including a deal with Eli Lilly to develop and commercialize a new treatment for type 2 diabetes.

Zealand Pharma's pipeline is packed with promising candidates, including a peptide-based GLP-1 receptor agonist that has shown impressive results in clinical trials.

The company's commitment to research and development has paid off, with several of its treatments already gaining approval in key markets.

Research and Development

Zealand Pharma is a company that doesn't promote and sell products themselves, but rather partners with pharmaceutical companies to bring their products to market. They have a strong portfolio of medications, including Lyxumia, which is a diabetes medication developed in collaboration with Sanofi.

One of their notable partnerships is with Sanofi, with whom they've developed several products, including Lyxumia, which is in the registration phase for diabetes type II treatment in the ex-US market. They've also collaborated with other companies, such as Abbvie and Roche, on various medications.

Credit: youtube.com, Zealand Pharma's new drug petrelintide will help people lose weight: CEO

Here are some of Zealand Pharma's notable medications and their development phases:

Zealand Pharma is also developing orphan drugs with government assistance, and they've acquired the rights to develop and sell the pre-clinical candidate medication ET3764 through the acquisition of Encycle Therapeutics.

Product Development

Zealand Pharma has a unique approach to product development, partnering with international pharmaceutical companies to bring their products to market.

They're particularly known for Lyxumia, a diabetes medication developed in collaboration with Sanofi. This partnership has been successful, with Lyxumia already in registration phase for type II diabetes outside of the US.

Zealand Pharma is also working on several other projects, including Danegaptid, a medication aimed at preventing heart tissue injuries in angioplasty patients. This project is currently in phase II.

The company has a diverse portfolio of products, including orphan drugs developed with government assistance. They've also acquired the rights to develop and sell ET3764, a pre-clinical candidate medication for alimentary tract diseases.

Here's an overview of some of their current projects:

Patents

Credit: youtube.com, Patent Landscape: The GPS for Your R&D Journey.

Zealand Pharma has filed a significant number of patents, totaling 140.

These patents cover a range of innovative ideas, including the multi-cartridge fluid delivery device, which was granted on March 11, 2025.

The application date for this patent was October 1, 2021, marking the beginning of the patent process.

Here's a brief overview of the patent's status and related topics:

Industry Insights

Zealand Pharma has a strong presence in the GLP-1 receptor agonist market, with its flagship product, liraglutide, being a leading treatment for type 2 diabetes.

The company has a long history of innovation, dating back to its founding in 1998, and has a reputation for developing novel peptide-based therapeutics.

Zealand Pharma's GLP-1 receptor agonists have shown impressive results in clinical trials, with liraglutide demonstrating significant improvements in glycemic control and weight loss in patients with type 2 diabetes.

Competitor Comparison

Let's take a closer look at the competitors in the industry. Zealand Pharma AS is a public company based in Soeborg, Denmark.

Credit: youtube.com, 7 Easy Steps on How to Perform a Competitor Analysis

The company has a relatively small team of 424 employees. In contrast, Genmab AS, another public company based in Denmark, has a significantly larger workforce with 2,639 employees.

Bavarian Nordic AS, also a public company based in Denmark, has 1,605 employees on its team. Ascendis Pharma AS, a public company based in Hellerup, Denmark, has 1,017 employees.

Cyclenium Pharma Inc, a private company based in Montreal, Canada, doesn't provide information on its employee count.

Here's a summary of the companies' headquarters and employee counts:

Premium Industry Data

Premium industry data is a game-changer for businesses looking to stay ahead of the curve. It provides valuable insights into market trends, consumer behavior, and competitor activity.

The average company can expect to see a 20% increase in sales within the first year of using premium industry data. This is because it allows businesses to make informed decisions based on hard data rather than intuition.

According to recent studies, 75% of businesses that use premium industry data report improved decision-making. This is likely due to the fact that it provides a clear and unbiased view of the market.

Related reading: Cynergy Data

Dynamic team of professionals collaborating around a table in a modern office setting, fostering innovation.
Credit: pexels.com, Dynamic team of professionals collaborating around a table in a modern office setting, fostering innovation.

One key area where premium industry data shines is in the realm of market research. By analyzing large datasets, businesses can gain a deeper understanding of their target audience and tailor their marketing efforts accordingly.

In fact, a recent survey found that 9 out of 10 businesses that use premium industry data report improved customer satisfaction. This is likely due to the fact that it allows businesses to create targeted marketing campaigns that speak directly to their customers' needs.

By leveraging premium industry data, businesses can stay ahead of the competition and make informed decisions that drive growth and success.

Key Information

Zealand Pharma's stock has seen some fluctuations, with an open price of 456.80 and a high of 465.00.

The bid and offer prices are currently at 464.80, indicating a stable market for the company's shares. The previous close was 456.90, showing a slight increase from the open price.

Here are some key statistics to keep in mind:

Key Statistics

A tranquil New Zealand beach scene at sunset with pilings and gentle waves.
Credit: pexels.com, A tranquil New Zealand beach scene at sunset with pilings and gentle waves.

The open price for this stock is 456.80, which is a good starting point for analysis.

The high price reached during the trading day was 465.00, indicating a potential for growth.

The low price was 455.50, showing some volatility in the market.

The current bid price is 464.80, which is close to the offer price of 464.80.

The previous close was 456.90, providing a basis for comparison.

The average volume traded was 297.05k shares, which is a relatively high number.

Here is a summary of the key statistics:

Marketed Drugs

Zealand Pharma AS has a commercialized product portfolio that's worth exploring.

Their marketed drugs include Das glucaconjugate, which is used to treat type 2 diabetes.

This product is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps regulate blood sugar levels.

Das glucaconjugate has been shown to improve glycemic control and reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes.

Zealand Pharma AS's marketed drugs also include Das glucaconjugate in combination with other medications for the treatment of type 2 diabetes.

This combination therapy has been found to be effective in improving glycemic control and reducing the risk of cardiovascular events in patients with type 2 diabetes.

Expand your knowledge: African Risk Capacity

News and Updates

Credit: youtube.com, Zealand Pharma CEO: Magnitude of obesity pandemic requires many more solutions

Zealand Pharma is a developer of novel variants of peptide drugs. This focus on peptides is a key aspect of their approach to pharmaceutical development.

Their expertise in peptides has led to the creation of innovative treatments for various medical conditions.

Zealand Pharma is committed to pushing the boundaries of what's possible with peptide-based therapies.

Frequently Asked Questions

Is Zealand Pharma a buy?

Zealand Pharma has a Strong Buy consensus rating with 3 buy ratings and no sell ratings, indicating a high potential for growth. Analysts predict a 62.52% upside potential, with a 12-month average price target of 105.67.

What does Zealand Pharma do?

Zealand Pharma is a biotechnology company focused on innovative peptide research and development, with a mission to address global health challenges through targeted therapies. Our expertise is dedicated to tackling complex conditions like obesity, rare diseases, and chronic inflammation.

Is Zealand Pharma a public company?

Yes, Zealand Pharma is a publicly traded company listed on Nasdaq Copenhagen under the ticker symbol ZEAL. You can access investor information, including the current share price in DKK, on their website.

Ginger Wolf

Copy Editor

Ginger Wolf is a meticulous and detail-oriented copy editor with a passion for refining written content. With a keen eye for grammar and syntax, Ginger has honed her skills in ensuring that articles are polished and error-free. Her expertise spans a range of topics, including personal finance and budgeting.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.